AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Gilead Sciences, Inc.
Video analysis: GILD
All videosNo video analysis for this stock yet. Request one from our team.
News: GILD
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD
Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 3.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 292,295 shares of the biopharmaceutical company's stock after buying an additional 10,206
Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
Gilead Sciences (NASDAQ: GILD - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 83.7% of Gilead Sciences shares
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabili
